دورية أكاديمية
Efficacy and Safety of Vildagliptin for Type 2 Diabetes in Patients With Diabetic Kidney Disease.
| العنوان: | Efficacy and Safety of Vildagliptin for Type 2 Diabetes in Patients With Diabetic Kidney Disease. |
|---|---|
| المؤلفون: | Mima A; Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, Japan akira.mima@ompu.ac.jp., Nakamoto T; Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, Japan., Saito Y; Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, Japan., Matsumoto K; Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, Japan., Lee S; Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, Japan. |
| المصدر: | In vivo (Athens, Greece) [In Vivo] 2024 Jul-Aug; Vol. 38 (4), pp. 1829-1833. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8806809 Publication Model: Print Cited Medium: Internet ISSN: 1791-7549 (Electronic) Linking ISSN: 0258851X NLM ISO Abbreviation: In Vivo Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2000- > : Attiki, Greece : International Institute of Anticancer Research Original Publication: Athens : Dr. J.G. Delinassios |
| مواضيع طبية MeSH: | Vildagliptin*/therapeutic use , Vildagliptin*/adverse effects , Vildagliptin*/administration & dosage , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/complications , Diabetic Nephropathies*/drug therapy , Glomerular Filtration Rate*/drug effects , Blood Glucose*/drug effects , Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use , Dipeptidyl-Peptidase IV Inhibitors*/adverse effects , Glycated Hemoglobin*/metabolism , Glycated Hemoglobin*/analysis , Adamantane*/analogs & derivatives , Adamantane*/therapeutic use , Adamantane*/adverse effects , Pyrrolidines*/therapeutic use , Pyrrolidines*/adverse effects , Pyrrolidines*/administration & dosage , Nitriles*/therapeutic use , Nitriles*/adverse effects , Nitriles*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Aged ; Treatment Outcome ; Creatinine/blood |
| مستخلص: | Background/aim: Vildagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors that have been shown to improve hyperglycemia in clinical trials among patients with type 2 diabetes. However, few studies have examined the efficacy of vildagliptin in patients with diabetic kidney disease (DKD). Patients and Methods: Eight patients with DKD received oral vildagliptin 50-100 mg/day. The duration of diabetes was 6.7±5.9 years and observation period was 23.6±9.8 months. Changes in fasting blood glucose, and hemoglobin A1c (HbA1c), estimated glomerular filtration rate (eGFR), and urine protein-to-creatinine ratio (UPCR) were studied before and after the administration of vildagliptin. Results: Vildagliptin treatment significantly decreased fasting blood glucose and HbA1c, compared to baseline (132±56 mg/dl, p=0.036, 6.0±0.3, p=0.041, respectively). UPCR tended to be decreased, albeit without statistical significance. However, eGFR was decreased after the administration of vildagliptin. No significant adverse effects were observed in all patients during the study. Conclusion: Although the sample size was limited and the observation period was brief, vildagliptin was found to be an effective and reasonably well-tolerated treatment for patients with DKD. (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.) |
| References: | Metabol Open. 2023 Mar 22;18:100240. (PMID: 37025096) Heliyon. 2022 Feb 03;8(2):e08878. (PMID: 35265754) In Vivo. 2023 Mar-Apr;37(2):825-829. (PMID: 36881056) Metabol Open. 2023 Feb 24;17:100236. (PMID: 36923991) N Engl J Med. 2001 Sep 20;345(12):861-9. (PMID: 11565518) Lancet. 2019 Jul 13;394(10193):121-130. (PMID: 31189511) Adv Ther. 2022 Aug;39(8):3488-3500. (PMID: 35751762) N Engl J Med. 2017 Nov 30;377(22):2197-2198. (PMID: 29171823) Sci Rep. 2020 Apr 1;10(1):5775. (PMID: 32238837) Lancet. 2019 Oct 26;394(10208):1519-1529. (PMID: 31542292) Kidney Int. 2011 Apr;79(8):883-96. (PMID: 21228767) PLoS One. 2018 Aug 2;13(8):e0201535. (PMID: 30071057) FEBS Open Bio. 2018 Feb 26;8(4):664-670. (PMID: 29632818) N Engl J Med. 1993 Sep 30;329(14):977-86. (PMID: 8366922) Diabetes. 2014 Jun;63(6):2120-31. (PMID: 24574044) Sci Rep. 2022 Oct 21;12(1):17630. (PMID: 36271110) J Diabetes Res. 2021 Dec 24;2021:2182225. (PMID: 34977254) Lab Invest. 2006 Sep;86(9):927-39. (PMID: 16767106) Diabetes. 2008 Jun;57(6):1712-22. (PMID: 18285555) Semin Nephrol. 2012 Sep;32(5):471-8. (PMID: 23062988) Lancet. 1998 Sep 12;352(9131):837-53. (PMID: 9742976) N Engl J Med. 2016 Nov 10;375(19):1834-1844. (PMID: 27633186) Cell Metab. 2006 Mar;3(3):153-65. (PMID: 16517403) J Diabetes Complications. 2018 Jul;32(7):720-725. (PMID: 29880432) Biomed Pharmacother. 2023 Sep;165:115032. (PMID: 37331253) Metabol Open. 2023 Jul 08;19:100251. (PMID: 37497038) J Diabetes Res. 2016;2016:1379274. (PMID: 26881236) JCI Insight. 2018 Dec 6;3(23):. (PMID: 30518693) Adv Ther. 2021 May;38(5):2201-2212. (PMID: 33860925) Diabetes. 2012 Nov;61(11):2967-79. (PMID: 22826029) JAMA. 2019 Jan 1;321(1):69-79. (PMID: 30418475) N Engl J Med. 1993 Nov 11;329(20):1456-62. (PMID: 8413456) |
| فهرسة مساهمة: | Keywords: Vildagliptin; diabetic kidney disease (DKD); dipeptidyl peptidase-4 (DPP-4) inhibitors; fasting blood glucose; hemoglobin A1c (HbA1c) |
| المشرفين على المادة: | I6B4B2U96P (Vildagliptin) 0 (Blood Glucose) 0 (Dipeptidyl-Peptidase IV Inhibitors) 0 (Glycated Hemoglobin) PJY633525U (Adamantane) 0 (Pyrrolidines) 0 (Nitriles) AYI8EX34EU (Creatinine) |
| تواريخ الأحداث: | Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240704 |
| رمز التحديث: | 20240704 |
| مُعرف محوري في PubMed: | PMC11215575 |
| DOI: | 10.21873/invivo.13635 |
| PMID: | 38936943 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1791-7549 |
|---|---|
| DOI: | 10.21873/invivo.13635 |